FAK and Interacting Proteins as Therapeutic Targets in Pancreatic Cancer

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)


Volume 16, 12 Issues, 2016


Download PDF Flyer




Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

FAK and Interacting Proteins as Therapeutic Targets in Pancreatic Cancer



Anti-Cancer Agents in Medicinal Chemistry, 10(10): 742-746.

Author(s): Deniz A. Ucar and Steven N Hochwald.

Affiliation: University of Florida, Department of Surgery, 1600 S.W. Archer Road, Room 6164; Box 100109, Gainesville, Florida 32610-0109, USA.

Abstract

Pancreatic cancer is the fourth leading cause of cancer death in the United States. Chemotherapy and radiation therapy have had minimal ability to alter the natural course of the disease. Clearly, additional agents are needed to improve outcomes in this aggressive cancer. Pancreatic cancer has been found to have several genetic alterations including activation of K-ras and inactivation of p53, p16, and DPC4. Other alterations include upregulation of angiogenic factors and matrix metalloproteinases, dysregulation of growth factor receptors, and cytoplasmic kinases including focal adhesion kinase (FAK) and src. Clinicians must translate the available knowledge of the molecular basis of this disease into rationale and effective therapeutic strategies for treatment. The role of FAK in the pathogenesis of pancreatic cancer is discussed below and efforts aimed at the development of inhibitors of FAK for this disease are reviewed.

Keywords:

Pancreatic Cancer, Focal Adhesion Kinase, Review, Therapeutic Targets, Chemotherapy, K-ras, angiogenic factors, src, siRNA, gemcitabine chemotherapy, Malignant, MMPs, VEGF, FRNK.



Purchase Online Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 10
Issue Number: 10
First Page: 742
Last Page: 746
Page Count: 5
DOI: 10.2174/187152010794728675
Price: $58
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science